Jeffrey Mcmahon

Title: Innovations by Jeffrey McMahon in Treating Psoriasis

Introduction

Jeffrey McMahon is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of dermatology, particularly in the treatment of generalized pustular psoriasis (GPP). His innovative approach focuses on utilizing chemokine receptor antagonists to address this challenging condition.

Latest Patents

McMahon holds a patent for "Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2." This patent outlines methods for treating GPP by administering effective amounts of Chemokine Receptor 6 (CCR6) antagonists and/or C-X-C motif chemokine receptor 2 (CXCR2) antagonists. The patent also discusses methods for modulating dysregulated IL-36 signaling and reducing the accumulation of neutrophils, inflammatory dendritic cells, and CD4 T cells in affected subjects.

Career Highlights

Jeffrey McMahon is associated with Chemocentryx, Inc., a company known for its focus on innovative therapies for autoimmune diseases. His work has been pivotal in advancing treatment options for patients suffering from GPP, showcasing his dedication to improving patient outcomes through scientific research and innovation.

Collaborations

Some of McMahon's notable coworkers include James J Campbell and Karen Ebsworth. Their collaborative efforts contribute to the ongoing research and development of effective treatments in the field of dermatology.

Conclusion

Jeffrey McMahon's innovative work in treating generalized pustular psoriasis highlights the importance of targeted therapies in modern medicine. His contributions continue to pave the way for advancements in the treatment of complex dermatological conditions.